Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents
Introduction
Several lines of evidence implicate dysfunction of glutamatergic system in the pathophysiology of schizophrenia, including post-mortem data showing changes in schizophrenic brains, which possibly arise from abnormal glutamatergic neurotransmission (Harrison, 1999), behavioral data indicating a psychotic-like action of NMDA receptor antagonists (e.g. phencyclidine (PCP), dizocilpine (MK-801)) in animals and humans (e.g. Krystal et al., 2003), and cognitive abnormalities produced by NMDA receptor antagonists, similar to those observed in schizophrenic patients (Moghaddam, 2004). Since decreased activation of NMDA receptor may result in psychotic symptoms, positive modulation of NMDA receptor became to be considered as a possible strategy for the treatment of schizophrenia. Indeed, a pharmacological enhancement of NMDA receptor function has been shown to induce positive therapeutic effects in clinical trials (Coyle et al., 2002).
The discovery of mGlu receptors has led to proposals that these modulatory glutamate receptors might be a target for psychotropic (i.e. antidepressant, anxiolytic and antipsychotic drugs) (Moghaddam, 2004, Palucha and Pilc, 2007). Group II and III mGlu receptors have mainly presynaptic localization (Schoepp, 2001) and serve as autoreceptors at brain structures (Gereau and Conn, 1995, Manzoni and Bockaert, 1995, Ugolini and Bordi, 1995, Cartmell and Schoepp, 2000). Their activation at glutamatergic nerve terminals was shown to cause a decrease in glutamate release, resulting in a functional antagonist of the glutamatergic system (Lovinger and McCool, 1995, Manzoni et al., 1995).
Behavioral studies indicated that selective agonists and positive modulators of group II mGlu receptors induce antipsychotic-like effects in rodents (Galici et al., 2005, Galici et al., 2006, Cartmell et al., 1999, Benneyworth et al., 2007). Moreover, a recent clinical study of Patil et al. (2007) showed that LY2140023, a prodrug of the selective group II mGlu receptor agonist LY404039, produced significant improvements in both positive and negative symptoms of schizophrenia compared to placebo, in a double-blind, placebo-controlled trial. Thus, activation of presynaptic mGlu receptors seems to be a possible strategy for the treatment of schizophrenia.
Similarly to mGlu2/3 receptors, group III mGlu receptors are highly expressed in the cerebral cortex and limbic areas of the brain and their activation inhibits glutamate release via presynaptical mechanism (Cartmell and Schoepp, 2000, Schoepp, 2001), however, they have been less studied, mainly due to the lack of high-affinity, highly selective and brain-penetrating agents. Recent studies showed that ACPT-I, a selective group III mGlu receptor agonist (Goudet et al., 2008), induced behavioral effects in animal models of anxiety, Parkinson's disease and pain (Pałucha et al., 2004, Goudet, 2008, Konieczny et al., 2007). However, this drug was never investigated after peripheral administration. In the present study we used ACPT-I to evaluate influence of group III mGlu receptor activation in rat and mouse models previously used to evaluate antipsychotic effects of group II mGlu receptor agonists (e.g. see Gewirtz and Marek, 2000, Rorick-Kehn et al., 2007). We used amphetamine and MK-801-induced hyperactivity models (Andine et al., 1999, Geyer and Ellenbroek, 2003) and (±)1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced head twitches (Gewirtz and Marek, 2000) with predictive validity of psychosis or hallucinations. Electrophysiological studies with cortical slices demonstrated that serotonin, as well as hallucinogen ((±)1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)), induces a robust increase in spontaneous EPSPs in layer V pyramidal neurons (Aghajanian and Marek, 2000). Therefore, we performed electrophysiological studies on the effect of ACPT-I on DOI-induced EPSPs slices from mouse brain frontal cortices. Results show that ACPT-I induces potential antipsychotic effects in all used behavioral models and that it suppresses DOI-induced frequency and amplitude of spontaneous EPSPs in slices from mouse brain frontal cortices. These data suggest that group III mGlu receptors constitute promising targets for the treatment of schizophrenia.
Section snippets
Animals and housing
Male Wistar rats were used to assess MK-801-induced and amphetamine-induced hyperlocomotion (weight ranges: 280–320 g and 197–233 g, respectively), while male Albino Swiss mice (20–25 g) were used to investigate anti-hallucinogenic activity in the head twitch test and for electrophysiological studies. The animals were kept under a 12:12 light–dark cycle at a room temperature of 19–21 °C, with free access to food and tap water before the experiment. Each experimental group consisted of 9–12
Effect of ACPT-I on the spontaneous locomotor activity in rats
Oral administration of the group III mGlu receptor agonist ACPT-I dose-dependently affected spontaneous locomotor activity relative to vehicle controls. Two-way ANOVA revealed a significant time effect (F(5,169) = 12.74, P < 0.0001) and the dose effect (F(3,169) = 12.884, P < 0.0001). Post-hoc test indicated that relative to the vehicle group, locomotor activity was significantly lower in rats receiving 30 mg/kg ACPT-I after 15, 20, 25 and 30 min and in rats receiving 100 mg/kg of ACPT-I, after 15–30 min,
Discussion
These studies examined the effects of the selective group III mGlu receptor agonist, ACPT-I in behavioral models predictive of psychosis and hallucinations, such as MK-801-induced and amphetamine-induced hyperlocomotion in rats and DOI-induced head twitches in mice. Moreover, electrophysiological effects of ACPT-I on DOI-induced EPSPs in mice were investigated.
Orally administered, ACPT-I in a dose-dependent manner inhibited spontaneous locomotor activity of rats, suggesting an effect similar to
Acknowledgement
This work was supported by Institute of Pharmacology PAS, Kraków.
References (48)
- et al.
Effects of single and repeated phencyclidine administration of the expression of metabotropic glutamate receptor subtype mRNAs in rat brain
Neuropsychopharmacology
(2001) - et al.
Serotonin model of schizophrenia: emerging role of glutamate mechanisms
Brain Res. Rev.
(2000) - et al.
Stereotyped behavior patterns and hyperactivity induced by amphetamine and apomorphine after discrete 6-hydroxydopamine lesions of extrapyramidal and mesolimbic nuclei
Brain Res.
(1977) - et al.
Behavioral evidence for interactions between a hallucinogenic drug and Group II metabotropic glutamate receptors
Neuropsychopharmacology
(2000) - et al.
Animal behavior models of the mechanisms underlying antipsychotic atypicality
Prog. Neuro-psychopharmacol. Biol. Psychiatry
(2003) - et al.
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Life Sci.
(1984) - et al.
Group III metabotropic glutamate receptors inhibit hyperalgesia in animal models of inflammation and neuropathic pain
Pain
(2008) - et al.
Dopamine receptor antagonists block amphetamine- and phencyclidine-induced motor stimulation in rats
Pharmacol. Biochem. Behav.
(1994) - et al.
Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice
Pharmacol. Biochem. Behav.
(2002) - et al.
The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats
Neuroscience
(2007)
Pharmacology of metabotropic glutamate receptors at the mossy fiber synapses of the guinea pig hippocampus
Neuropharmacology
Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors
Eur. J. Pharmacol.
Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs
Pharmacol. Ther.
Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats
Neuropharmacology
Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophrenia
Brain Res.
Pharmacological agents acting at subtypes of metabotropic glutamate receptors
Neuropharmacology
Metabotropic glutamate group II receptors are responsible for the depression of synaptic transmission induced by ACPD in the dentate gyrus
Eur. J. Pharmacol.
The regulation of quantal size
Prog. Neurobiol.
Characterization of MK-801-induced behavior as a putative rat model of psychosis
J. Pharmacol. Exp. Ther.
A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis
Mol. Pharmacol.
Action de la caféine sur la motilité spontanée de la souris
Arch. Int. Pharmacodyn. Ther.
Regulation of neurotransmitter release by metabotropic glutamate receptors
J. Neurochem.
The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats
J. Pharmacol. Exp. Ther.
Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists
Neuropsychopharmacology
Cited by (42)
The mGlu<inf>7</inf> receptor in schizophrenia - An update and future perspectives
2022, Pharmacology Biochemistry and BehaviorCitation Excerpt :Thus, pharmacological modulation of their action could counteract the disinhibition of glutamatergic neurons caused by NMDA receptor dysfunction with high probability. The first report concerning the antipsychotic efficacy of group III receptor ligands was released in 2008 and concerned the activity of a nonselective orthosteric agonist of the receptor (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid, ACPT-1 (Pałucha-Poniewiera et al., 2008). The compound reversed DOI-induced head twitches and MK-801- or amphetamine-induced hyperactivity, which predict positive symptoms of schizophrenia.
Cortical influences of serotonin and glutamate on layer V pyramidal neurons
2021, Progress in Brain ResearchCitation Excerpt :The high potency and the shallow shape of the mGlu4/8 receptor agonist PPG in suppressing 5-HT-induced EPSCs as well as suppression of the blockade of this effect by the group III mGlu receptor antagonist CPPG suggests activation of mGlu8 receptors mediates, at least in part, a portion of the suppression of 5-HT-induced EPSCs (Zhang and Marek, 2007). Another group III mGlu receptor agonist was also found to suppress spontaneous DOI-induced EPSCs when recording from mouse cortical layer V pyramidal cells (Palucha-Poniewiera et al., 2008). Thus, both activation of both mGlu4 and mGlu8 receptors appear to suppress, at least in part, the 5-HT-induced EPSCs when recording from rodent mPFC/neocortical layer V pyramidal cells.
The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia
2018, Current Opinion in PharmacologyNeurochemical and behavioral studies on the 5-HT<inf>1A</inf>-dependent antipsychotic action of the mGlu<inf>4</inf> receptor agonist LSP4-2022
2017, NeuropharmacologyCitation Excerpt :All of the subtypes are negatively linked to adenylyl cyclase activity, and their activation inhibits glutamate release (Linden and Schoepp, 2006; Conn and Pin, 1997). Data on the antipsychotic-like activity of the ligands of these receptors were published by Palucha-Poniewiera et al. (2008) for a non-selective agonist of these receptors, ACPT-1 (Acher et al., 1997). These data were concerned mainly with its activity in the tests for positive symptoms of schizophrenia.
Metabotropic glutamate receptors as targets for new antipsychotic drugs: Historical perspective and critical comparative assessment
2016, Pharmacology and Therapeutics